Biotech Values

[DewDiligence]

ARIA—The drug hasn't even been approved and you are anticipating generics. In any event Ponatinib would have to be very successful for development of a generic to be considered.

I’m referring to generics in the next few years for Gleevec (a certainty) and Sprycel (a possibility), not to generics for Ponatinib.